Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India

Bigner, 1999, Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization, Am J Pathol, 155, 375, 10.1016/S0002-9440(10)65134-6 Cairncross, 1998, Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas, J Natl Cancer Inst, 90, 1473, 10.1093/jnci/90.19.1473 Kraus, 1995, Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma, J Neuropathol Exp Neurol, 54, 91, 10.1097/00005072-199501000-00011 Maintz, 1997, Molecular genetic evidence for subtypes of oligoastrocytomas, J Neuropathol Exp Neurol, 56, 1098, 10.1097/00005072-199710000-00003 Reifenberger, 1994, Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p, Am J Pathol, 145, 1175 Smith, 1999, Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype, Oncogene, 18, 4144, 10.1038/sj.onc.1202759 Smith, 2000, Alterations of chromosome arms 1 p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas, J Clin Oncol, 18, 636, 10.1200/JCO.2000.18.3.636 He, 2001, Glioblastomas with an oligodendroglial component: a pathological and molecular study, J Neuropathol Exp Neurol, 60, 863, 10.1093/jnen/60.9.863 Kraus, 2001, Molecular genetic alterations in glioblastomas with oligodendroglial component, Acta Neuropathol, 101, 311, 10.1007/s004010000258 Nakamura, 2000, Loss of heterozygosity on chromosome 19 in secondary glioblastomas, J Neuropathol Exp Neurol, 59, 539, 10.1093/jnen/59.6.539 Schmidt, 2002, Impact of genotype and morphology on the prognosis of glioblastoma, J Neuropathol Exp Neurol, 61, 321, 10.1093/jnen/61.4.321 von Deimling, 2000, Comprehensive allelotype and genetic analysis of 466 human nervous system tumors, J Neuropathol Exp Neurol, 59, 544, 10.1093/jnen/59.6.544 Brat, 2004, Radiation Therapy Oncology Group. Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials, Neuro Oncol, 6, 96, 10.1215/S1152851703000231 Fathi, 2007, Objective response to radiation therapy and long-term survival of patients with WHO grade II astrocytic gliomas with known LOH 1p/19q status, Strahlenther Onkol, 183, 517, 10.1007/s00066-007-1673-6 Ueki, 2002, Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors, Clin Cancer Res, 8, 196 von Deimling, 1994, Loci associated with malignant progression in astrocytomas: a candidate on chromosome 19q, Cancer Res, 54, 1397 Nagasaka, 2000, 1p/19q deletion/imbalance for molecular subclassification of glioblastoma, Brain Tumor Pathol, 24, 1, 10.1007/s10014-006-0209-6 Pinto, 2008, Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis, Virchows Arch, 452, 481, 10.1007/s00428-007-0562-9 Nelson, 1996, Glioblastoma with oligodendroglial features (GBM-OL): report from Radiation Therapy Oncology Group (RTOG) trial 8302, Lab Invest, 74, 141A Hoang-Xuan, 2001, Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression, Neurology, 57, 1278, 10.1212/WNL.57.7.1278 Kleihues, 2007, WHO grading of tumours of the central nervous system, 10 Hartmann, 2005, Molecular genetic analysis of oligodendroglial tumors, J Neuropathol Exp Neurol, 64, 10, 10.1093/jnen/64.1.10 Petitjean, 2007, Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database, Hum Mutat, 28, 622, 10.1002/humu.20495 Eoli, 2006, Molecular markers of gliomas: a clinical approach, Neurol Res, 28, 538, 10.1179/016164106X116827 Hunter, 2003, Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy, Int J Oncol, 23, 857 Kondo, 2004, Molecular targeting for malignant gliomas, Int J Oncol, 24, 1101 Louis, 2006, Molecular pathology of malignant gliomas, Annu Rev Pathol, 1, 97, 10.1146/annurev.pathol.1.110304.100043 Ohgaki, 2005, Population based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendrogliomas, J Neuropathol Exp Neurol, 64, 479, 10.1093/jnen/64.6.479 Gresner, 2007, Gliomas: association of histology and molecular genetic analysis of chromosomes 1p, 10q, and 19q, Acta Neurobiol Exp (Wars), 67, 103 Jeon, 2007, Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization, Neuropathol, 27, 10, 10.1111/j.1440-1789.2006.00735.x Reddy, 2008, Assessment of 1p/19q deletions by fluorescence in situ hybridization in gliomas, Cancer Genet Cytogenet, 184, 77, 10.1016/j.cancergencyto.2008.03.009 Watanabe, 2002, Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas, Acta Neuropathol, 103, 267, 10.1007/s004010100464 Iwamoto, 2008, Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas, J Neurooncol, 88, 293, 10.1007/s11060-008-9563-z von Deimling, 1992, Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas, Cancer Res, 52, 4277 Homma, 2006, Correlation among pathology, genotype, and patient outcomes in glioblastoma, J Neuropathol Exp Neurol, 65, 846, 10.1097/01.jnen.0000235118.75182.94 Pollack, 2003, Association between chromosome 1p and 19q loss and outcome in pediatric malignant gliomas: results from the CCG-945 cohort, Pediatr Neurosurg, 39, 114, 10.1159/000071647 Rosenberg, 1996, Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412– STD interval, Oncogene, 13, 2483 von Deimling, 1993, Subsets of glioblastoma multiforme defined by molecular genetic analysis, Brain Pathol, 3, 19, 10.1111/j.1750-3639.1993.tb00721.x Watanabe, 1996, Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas, Brain Pathol, 6, 217, 10.1111/j.1750-3639.1996.tb00848.x Griffin, 2006, Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss, J Neuropathol Exp Neurol, 65, 988, 10.1097/01.jnen.0000235122.98052.8f Kros, 1999, Genetic aberrations in oligodendroglial tumours: an analysis using comparative genomic hybridization (CGH), J Pathol, 188, 282, 10.1002/(SICI)1096-9896(199907)188:3<282::AID-PATH355>3.0.CO;2-S Smith, 2000, Mapping of the chromosome 19q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers, Genes Chromosomes Cancer, 29, 16, 10.1002/1098-2264(2000)9999:9999<::AID-GCC1007>3.3.CO;2-9 Vordermark, 2006, Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26), BMC Cancer, 18, 247, 10.1186/1471-2407-6-247 Scheithauer, 2008, The 2007 WHO classification of tumors of the nervous system: controversies in surgical neuropathology [Erratum in: Brain Pathol 2008;18:640], Brain Pathol, 18, 307, 10.1111/j.1750-3639.2008.00179.x